These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32732259)

  • 1. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.
    Paolilo RB; Hacohen Y; Yazbeck E; Armangue T; Bruijstens A; Lechner C; Apostolos-Pereira SL; Martynenko Y; Breu M; de Medeiros Rimkus C; Wassmer E; Baumann M; Papetti L; Capobianco M; Kornek B; Rostásy K; da Paz JA; Ciccarelli O; Lim M; Saiz A; Neuteboom R; Marignier R; Hemingway C; Sato DK; Deiva K
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32732259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Hacohen Y; Wong YY; Lechner C; Jurynczyk M; Wright S; Konuskan B; Kalser J; Poulat AL; Maurey H; Ganelin-Cohen E; Wassmer E; Hemingway C; Forsyth R; Hennes EM; Leite MI; Ciccarelli O; Anlar B; Hintzen R; Marignier R; Palace J; Baumann M; Rostásy K; Neuteboom R; Deiva K; Lim M
    JAMA Neurol; 2018 Apr; 75(4):478-487. PubMed ID: 29305608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.
    Zhou Y; Zhong X; Shu Y; Cui C; Wang J; Wang Y; Li X; Chen Z; Peng L; Kermode A; Qiu W
    Mult Scler Relat Disord; 2019 Feb; 28():213-220. PubMed ID: 30623860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    Wang R; Sun D; Wang X; Shi Z; Kong L; Du Q; Zhang Y; Chen H; Luo W; Zhang N; Zhou H
    J Neurol; 2024 Jul; 271(7):4503-4512. PubMed ID: 38703259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
    Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
    Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
    Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt.
    Kishk NA; Abdelfattah W; Shalaby NM; Shehata HS; Hassan A; Hegazy MI; Abokrysha NT; Abdellatif D; Shawky SM; Abdo SS; Taha N; Fouad AM; Elmazny A; Ragab AH
    BMC Neurol; 2021 Feb; 21(1):53. PubMed ID: 33535985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.